Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Daito Pharmaceutical Co., Ltd. ( (JP:4577) ).
Daito Pharmaceutical Co., Ltd. has released its financial results presentation materials for the nine months of the fiscal year ending May 2026. The company also outlined its full-year earnings forecast for fiscal 2026, providing investors and stakeholders with guidance on expected performance and strategic financial direction.
While detailed figures were not disclosed in the brief, the presentation signals ongoing transparency in financial reporting to the market. The inclusion of both interim results and full-year outlook helps market participants assess Daito Pharmaceutical’s operational momentum and earnings trajectory in the current fiscal year.
The most recent analyst rating on (JP:4577) stock is a Hold with a Yen1509.00 price target. To see the full list of analyst forecasts on Daito Pharmaceutical Co., Ltd. stock, see the JP:4577 Stock Forecast page.
More about Daito Pharmaceutical Co., Ltd.
Daito Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company listed on the Tokyo Stock Exchange Prime Market under ticker 4577. The company operates in the healthcare and pharmaceuticals industry, focusing on the development, manufacture, and sale of pharmaceutical products for the domestic market and potentially broader regional markets.
Average Trading Volume: 89,980
Technical Sentiment Signal: Buy
Current Market Cap: Yen43.09B
Find detailed analytics on 4577 stock on TipRanks’ Stock Analysis page.